{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:42:09Z","timestamp":1790484129833,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.amjms.2020.04.006","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T21:50:58Z","timestamp":1587073858000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia"],"prefix":"10.1016","volume":"360","author":[{"given":"Jennifer D.","family":"Twilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Algrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan H.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Samarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.amjms.2020.04.006_bib0001","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjms.2020.04.006_bib0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-0711-5-2","article-title":"Laboratory-based surveillance of current antimicrobial resistance patterns and trend among staphylococcus aureus: 2005 status in the United States","volume":"5","author":"Styers","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"2","key":"10.1016\/j.amjms.2020.04.006_bib0003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.amjms.2020.04.006_bib0004","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible staphylococcus aureus infections in the outpatient setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.amjms.2020.04.006_bib0005","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.amjms.2020.04.006_bib0006","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Disease Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.amjms.2020.04.006_bib0007","first-page":"e394","volume":"111","author":"Baddour","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.amjms.2020.04.006_bib0008","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00243-16","article-title":"Cefazolin versus nafcillin for methicillin-sensitive staphylococcus aureus bloodstream infection in a California tertiary medical center","volume":"60","author":"Pollett","year":"2016","journal-title":"Antimicrob AgentsChemother"},{"issue":"11","key":"10.1016\/j.amjms.2020.04.006_bib0009","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00485-11","article-title":"Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible staphylococcus aureus bacteremia?","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.amjms.2020.04.006_bib0010","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.00317-09","article-title":"Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible staphylococcus aureus: frequency and possible cause of cefazolin treatment failure","volume":"53","author":"Nannini","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"41","key":"10.1016\/j.amjms.2020.04.006_bib0011","doi-asserted-by":"crossref","first-page":"19688","DOI":"10.2807\/ese.15.41.19688-en","article-title":"Methicillin-resistant staphylococcus aureus (MRSA): burden of disease and control challenges in Europe","volume":"15","author":"Kock","year":"2010","journal-title":"Euro Surveill"},{"issue":"4","key":"10.1016\/j.amjms.2020.04.006_bib0012","doi-asserted-by":"crossref","first-page":"E309","DOI":"10.33321\/cdi.2014.38.51","article-title":"Australian staphylococcus aureus sepsis outcome programme annual report","volume":"38","author":"Coombs","year":"2014","journal-title":"Commun Dis Intell Q Rep"},{"issue":"Suppl 4","key":"10.1016\/j.amjms.2020.04.006_bib0013","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1086\/598185","article-title":"Clinical consensus conference: survey on gram-positive bloodstream infections with a focus on staphylococcus aureus","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.amjms.2020.04.006_bib0014","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.1977.03270330059022","article-title":"Unsuccessful treatment of staphylococcal endocarditis with cefazolin","volume":"237","author":"Bryant","year":"1977","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.amjms.2020.04.006_bib0015","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1001\/jama.1977.03270510023006","article-title":"Cefazolin and Staphylococcus aureus endocarditis","volume":"237","author":"Kaye","year":"1977","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.amjms.2020.04.006_bib0016","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/379021","article-title":"Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue","volume":"37","author":"Nannini","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjms.2020.04.006_bib0017","article-title":"A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible staphylococcus aureus bloodstream infections","author":"Miller","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"10.1016\/j.amjms.2020.04.006_bib0018","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000499033","article-title":"Does the beta-lactam matter? Nafcillin versus cefazolin for methicillin-susceptible staphylococcus aureus bloodstream infections.\u201d","volume":"63","author":"Burrelli","year":"2018","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1016\/j.amjms.2020.04.006_bib0019","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jac\/dku560","article-title":"Comparative effectiveness of cefzolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicenter cohort study","volume":"70","author":"Bai","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjms.2020.04.006_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","article-title":"Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible staphylococcus aureus (MSSA) bacteremia","volume":"15","author":"Wong","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"8","key":"10.1016\/j.amjms.2020.04.006_bib0021","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amjms.2020.04.006_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.amjms.2020.04.006_bib0023","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/mdr.2013.0229","article-title":"Clinical implications of cefazolin inoculum effect and \u03b2-lactamase type of methicillin-susceptible Staphylococcus aureus bacteremia","volume":"20","author":"Lee","year":"2014","journal-title":"Microb Drug Resist"},{"issue":"6","key":"10.1016\/j.amjms.2020.04.006_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy123","article-title":"The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible staphylococcus aureus bacteremia","volume":"5","author":"Miller","year":"2018","journal-title":"Open Forum Infect Dis"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920301233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920301233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:37:12Z","timestamp":1757702232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962920301233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0002962920301233"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2020.04.006","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2020.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}